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Key questions
What is already known about this subject?
 ► Comparative outcomes data for tricuspid valve re-
pair versus replacement inpatients with severe sec-
ondary tricuspid regurgitation are limited.
What does this study add?
 ► In patients with severe secondary tricuspid regur-
gitation, tricuspid valve replacement is associated 
with significantly higher rates of in-hospital death 
(12% vs 6.9%, p=0.009) and permanent pacemaker 
implantation (33.7% vs 11.2%, p<0.001).
How might this impact on clinical practice?
 ► In patients with severe secondary tricuspid regurgi-
tation and suitable anatomy, tricuspid repair is asso-
ciated with at least comparable outcomes compared 
with valve replacement.
 ► However, further comparative studies are needed to 
assess long-term outcomes of patients undergoing 
repair versus replacement.
AbstrAct
Background Comparative outcome data on tricuspid 
valve repair (TVr) versus tricuspid valve replacement 
(TVR) for severe secondary tricuspid regurgitation (TR) are 
limited.
Methods We used a national inpatient sample to assess 
in-hospital morbidity and mortality, length of stay and cost 
in patients with severe secondary TR undergoing isolated 
TVr versus TVR.
Results A total of 1364 patients (national estimate=6757) 
underwent isolated tricuspid valve surgery during 
the study period, of whom 569 (41.7%) had TVr and 
795 (58.3%) had TVR. There was no difference in the 
prevalence of major morbidities between the two groups, 
except for liver disease and hepatic cirrhosis, which 
were more common in the TVR group. Before propensity 
matching, in-hospital mortality was similar between 
patients who underwent isolated TVr and TVR (8.1% vs 
10.8%, p=0.093), but the incidence of postoperative 
morbidities differed: TVR was associated with higher 
rates of permanent pacemaker implantation and blood 
transfusion, while TVr was associated with more acute 
kidney injury. After rigorous propensity score matching, 
TVR was associated with significantly higher rates of in-
hospital death (12% vs 6.9%, p=0.009) and permanent 
pacemaker implantation (33.7% vs 11.2%, p<0.001). 
Postoperative morbidities and length of stay, however, 
were not different between the two groups. Nonetheless, 
cost of hospitalisation was 16% higher in the TVr group.
Conclusions In patients undergoing isolated surgery for 
secondary TR, TVR is associated with higher in-hospital 
mortality and need for permanent pacemaker compared 
with TVr. Further studies are needed to understand the 
impact of the type of surgery on the short-term and long-
term mortality in this complex undertreated population.
Secondary tricuspid regurgitation (TR) is the 
predominant cause of severe TR in North 
America.1 Despite the deleterious effect of 
severe TR on long-term outcomes, contem-
porary data on tricuspid valve (TV) surgery 
remain limited.2 This is likely multifactorial 
due to modest annual volume of TV surgery, 
under-recognition of TV disease, delayed 
clinical presentation, high prevalence of 
comorbidities in these patients, and lack of 
consensus on the approach and timing of TV 
surgery.3 Once the patient is referred for TV 
surgery for severe TR, the decision to repair 
or replace the valve is also complex and 
depends on the patient’s age and comorbidi-
ties, the degree of right ventricular dilatation 
and dysfunction, the need for a concomitant 
procedure, and surgical expertise. Compar-
ative outcome data on tricuspid valve repair 
(TVr) versus tricuspid valve replacement 
(TVR) for secondary TR are limited. A recent 
meta-analysis by Choi et al4 suggested more 
favourable outcomes with TVr, but this was 
confounded with the inclusion of patients 
with primary TR and concomitant opera-
tions. The purpose of this study is to assess 
in-hospital morbidity and mortality, length of 
stay and cost in patients with severe secondary 
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TR undergoing isolated TVr versus TVR using a contem-
porary national representative database.
MetHods
The Nationwide Inpatient Sample (NIS)3 was used to 
derive patient-relevant information between January 
2003 and December 2014. The NIS is the largest, publicly 
available, all-payer administrative claims-based database 
and contains information about patient discharges from 
~1000 non-federal hospitals in 45 states. It contains clinical 
and resource use information on 5–8 million discharges 
annually, with safeguards to protect the privacy of indi-
vidual patients, physicians and hospitals. The NIS shares 
certain similarities with the Medicare database, including 
the same International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) coding system 
for procedures and diagnoses. Contrary to the Medicare 
database, the NIS includes all payers and patients across 
all ages. These data are stratified to represent ~20% of US 
inpatient hospitalisations across different hospital and 
geographical regions (random sample). The national 
estimates (NE) represent a calculated estimate of the total 
(100%) US hospitalised population. This is calculated 
using the Agency for Healthcare Research and Quality 
sampling and weighting method. Outcomes analysis was 
performed using the actual 20% sample available in the 
NIS, whereas the trend analysis was performed using the 
NE.
Patients aged 18 years and older who underwent TVR 
(ICD-9-CM procedure code 35.27 and 35.28) and TVr 
(ICD-9-CM code 35.14) during the study period were 
identified. To identify patients with secondary TR, those 
with congenital TV disease (ICD-9-CM codes 764.1, 
746.2, 745.4 and 746.89) or those with infective endo-
carditis (ICD-9-CM code 571.2) were excluded. Patients 
who underwent redo TV surgery were also excluded 
(ICD-9-CM codes 35.20 and 35.21). To eliminate poten-
tial impact of concurrent cardiac surgery on outcomes, 
patients who underwent a concomitant valve surgery, 
coronary bypass grafting or surgical ablation for atrial 
fibrillation (maze procedure) were excluded. A flow 
chart of the study is provided in figure 1.
Patients who underwent isolated TV surgery for severe 
secondary TR were divided into two groups according to 
the surgical approach (group 1, isolated TVr; and group 
2, isolated TVR). We then performed a comparative anal-
ysis between the outcomes of isolated TVr and TVR in 
patients with severe secondary TR. To account for poten-
tial confounding factors and reduce the effect of selection 
bias, a propensity score matching model was developed 
using logistic regression to derive two matched groups 
for comparative outcomes analysis. Patients who under-
went isolated TVr or isolated TVR were entered into a 
nearest neighbour 1:1 variable ratio, parallel, balanced 
propensity matching model using a calliper of 0.01 to 
attain two pairs of well-matched cohort for outcomes 
analysis. Propensity scores were derived from 41 hospital, 
clinical and demographic covariates, including the Elix-
hauser Comorbidity Index. The primary endpoint was 
in-hospital death. The secondary outcomes included 
postoperative morbidities, length of stay, hospital charges 
and discharge disposition.
Patient-relevant descriptive statistics are presented as 
frequencies with percentages for categorical variables 
and as means with SD for continuous variables. Base-
line characteristics were compared between the groups 
using a Pearson’s χ2 test for categorical variables and 
an independent-samples t-test for continuous variables. 
A Cochran-Armitage test was used to evaluate trends in 
isolated TVr and isolated TVR in patients with severe 
secondary TR. Matched categorical variables were 
presented as frequencies with percentages and compared 
using McNemar’s test. Matched continuous variables were 
presented as means with SD and compared using a pair 
ed-samples t-test. All statistical analyses were performed 
using SPSS V.24 and R V.3.3.1.
Results
A total of 1364 actual reported cases (NE=6757) under-
went isolated TV surgery during the study period, of 
whom 569 (41.7%) had TVr and 795 (58.3%) had 
TVR (figure 2). Compared with patients who had TVr, 
those who underwent TVR were older (56±17 vs 54±18, 
p=0.02), were women (57.6% vs 51.1%, p=0.018) and 
were Caucasians (71.9% vs 64.6%, p=0.018). There was 
no difference in the prevalence of major morbidities 
between the two groups (table 1), except for liver disease 
and hepatic cirrhosis, which were more common in the 
TVR group (11.1% vs 3.7% and 5.8% vs 1.4%, respec-
tively, p<0.001 for all). Surgery was frequently performed 
during a non-elective admission in both groups but more 
commonly for TVr (45.8% vs 35%, p<0.001).
Before propensity score matching, in-hospital mortality 
was similar between patients who underwent isolated 
TVr or TVR (8.1% vs 10.8%, p=0.093), but the incidence 
of postoperative morbidities differed: TVR was associ-
ated with a threefold higher rate of permanent pace-
maker implantation (34.1% vs 10.9%, p<0.001) and a 
trend towards more blood transfusion (37.6% vs 32.7%, 
p=0.06), while TVr was associated with more acute kidney 
injury (33.7% vs 27.8%, p=0.018). Nonetheless, the need 
for renal replacement therapy following surgery was not 
different between the two groups (4.4% vs 5.5% following 
TVr vs TVR, p=0.34). Patients who had TVr had longer 
hospitalisations (23±26 vs 19±24, p=0.013), but both 
groups had comparable rates of non-home discharges 
(table 2). Temporal trends in in-hospital mortality 
following isolated TVR and TVr are shown in (online 
supplementary figure 1).
After rigorous propensity score matching, no signifi-
cant differences in baseline characteristic were observed 
(table 1). In propensity-matched patients, TVR was asso-
ciated with significantly higher rates of in-hospital death 
(12% vs 6.9%, p=0.009) and permanent pacemaker 
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Figure 1 Study flow chart. NE, national estimate; TR, tricuspid regurgitation; TVr, tricuspid valve repair; TVR, tricuspid valve 
replacement.
implantation (33.7% vs 11.2%, p<0.001). Postopera-
tive morbidities and length of stay, however, were not 
different between the two groups (table 2). Nonetheless, 
cost of hospitalisation was 16% higher in the TVr group.
disCussion
The following are the main findings of the present inves-
tigation: (1) Isolated tricuspid surgery for secondary 
TR is infrequently performed in the USA. (2) Patients 
undergoing isolated TVR versus TVr have similar base-
line characteristics, with the exception of chronic liver 
disease, which was more prevalent in the TVR group. (3) 
In propensity-matched cohorts of patients, isolated TVR 
is associated with 74% higher incidence of in-hospital 
mortality and 300% higher rate of permanent pacemaker 
implantation compared with isolated TVr. Although 
length of stay was comparable in both groups, cost of 
hospitalisation was 16% higher after TVr than after TVR.
It is estimated that 1.6 million patients in the USA 
suffer from moderate to severe TR.5 6 In the Framingham 
Study moderate or severe TR was present in 1.5% of men 
and 5.6% of women >70 years of age.7 The prevalence 
is higher in patients with concomitant valvular disease 
or cardiomyopathy. Moderate to severe TR is found in 
30%–50% of patients with severe mitral regurgitation, 
12%–25% of patients with severe aortic stenosis and 
19% of patients with congestive heart failure.8–12 The 
percentage of patients with symptomatic TR is uncertain 
and remains difficult to estimate given the high preva-
lence of other potential sources of symptoms and comor-
bidities in these patients.13 Nonetheless, the current 
study confirms that only a small fraction of patients at 
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figure 2 Temporal trend of isolated tricuspid valve surgery for secondary tricuspid regurgitation in the USA between 2003 
and 2014. TVr, tricuspid valve repair; TVR, tricuspid valve replacement. x axis, year; y axis, number of cases (weighted national 
estimates).
risk undergo isolated TV surgery in the USA. Among 
these patients, however, a slight majority undergoes TVR 
(58.3%) and the remainder undergo TVr.
Despite the relatively young age of patients in this 
cohort (55±17 years), major comorbidities were common 
(hypertension 43%, diabetes 18%, atrial fibrillation 
45%, coagulopathy 28% and chronic renal disease 
22%). Although both groups had comparable baseline 
risk profiles, the TVR group had higher prevalence of 
chronic liver disease. This is important and this could be 
related to a more advanced right ventricular disease and 
subsequent congestive hepatopathy, both are likely to 
contribute to worse short-term and long-term outcomes 
in the TVR group.
The decision of whether to repair or replace the TV is 
complex and depends on multiple factors: (1) timing of 
surgery, (2) anatomical factors and (3) clinical expertise. 
Unlike aortic or mitral valve disease, where the timing 
of operation may often be driven by symptoms, many 
patients with severe TR remain symptomatic for prolonged 
periods before being referred to surgical correction. At 
this point, patients have often developed severe tethering 
and marked right ventricular dysfunction that may inevi-
tably impact surgical outcomes. Anatomical factors, such 
as the degree of annular dilatation and leaflet tethering, 
play a significant role in determining the surgical therapy. 
Although TVr is usually the preferred approach in order 
to minimise bypass time, TVR is frequently needed in 
cases of extreme annular dilatation or leaflet abnor-
mality (such as in pacemaker-related TR)14 15 Patient 
choice, compliance and clinical expertise also influence 
the choice of TVr versus TVR. Bioprosthetic valve degen-
eration and mechanical valve thrombosis continue to 
generate much debate and may impact the decision to 
repair or replace in patients with compliance issues.16 
Similarly, experience with repair techniques is key to 
minimise risk of recurrence.17 The lack of such expe-
rience may also affect decision making on the surgical 
approach. Hence, selection bias will remain a significant 
confounder in any retrospective investigations pertaining 
to TV surgery. Notably, a high percentage of patients had 
bioprosthetic valve implantation in this study, likely due 
to concerns about non-compliance with lifelong antico-
agulation. Although we performed vigorous propensity 
score matching to account for differences in baseline 
risk profiles and hospital characteristics, the above-men-
tioned factors should be considered when interpreting 
the current study results.
In propensity-matched groups, TVR was associated 
with higher in-hospital mortality compared with TVr. 
Prior comparative studies on TVr versus TVR yielded 
conflicting data likely due to design issues and the inclu-
sion of heterogeneous groups of patients with various 
TR aetiologies.18–27 A recent comprehensive meta-anal-
ysis pooled data from 17 studies and compared TVr 
versus TVR in patients with severe TR for the primary 
endpoint of all-cause mortality.4 This meta-analysis 
showed that TVR was associated with higher mortality 
compared with TVr (HR 1.59, 95% CI 1.26 to 2.00) 
(I2=62%). A subanalysis including only studies with 
predominantly patients with secondary TR revealed 
that TVR remained associated with higher odds of 
all-cause mortality (HR 1.39, 95% CI 1.04 to 1.86). This 
is consistent with the current findings of a 74% higher 
risk of postoperative mortality following TVR versus 
TVr. The contribution of right ventricular dysfunction, 
duration of the TV disease, and surgical volume and 
techniques on this excess mortality in the TVR group 
cannot be ascertained due to the lack of data on disease 
duration or echocardiographic findings in the NIS and 
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Age (years), mean 
(SD)
54 (18) 56 (17) 0.021 55 (18) 55 (17) 0.818
Female, n (%) 291 (51.1) 458 (57.6) 0.018 259 (54.5) 259 (54.5) 0.99
White race 307 (64.6) 466 (71.9) 0.018 306 (64.4) 308 (64.8) 0.76
Black race 99 (20.8) 88 (13.6) 83 (17.5) 75 (15.8)
Hispanic race 35 (7.4) 49 (7.6) 39 (8.2) 37 (7.8)
Medical comorbidity
  Hypertension 241 (42.4) 346 (44) 0.56 209 (44) 205 (43.2) 0.838
  Diabetes 103 (18.1) 140 (17.6) 0.815 85 (17.9) 84 (17.7) 0.99
  Chronic lung 
disease
81 (14.2) 106 (13.3) 0.633 67 (14.1) 66 (13.9) 0.99
  Atrial fibrillation/
flutter
243 (42.7) 366 (46) 0.222 210 (44.2) 201 (42.3) 0.582
  Anaemia 120 (21.1) 175 (22) 0.683 99 (20.8) 99 (20.8) 0.99
  Coagulopathy 155 (27.3) 219 (27.9) 0.816 129 (27.2) 131 (27.6) 0.943
  Conduction 
abnormalities
17 (3) 23 (2.9) 0.919 11 (2.3) 12 (2.5) 0.99
  Vascular disease 37 (6.5) 54 (6.8) 0.832 33 (6.9) 29 (6.1) 0.688
  Chronic renal 
disease
125 (22) 183 (23) 0.647 100 (21.1) 101 (21.3) 0.99
  Haemodialysis 17 (3) 36 (4.5) 0.147 17 (3.6) 18 (3.8) 0.99
  Coronary artery 
disease
84 (14.8) 98 (12.3) 0.192 65 (13.7) 66 (13.9) 0.99
  Liver disease 21 (3.7) 87 (11.1) <0.001 20 (4.2) 27 (5.7) 0.265
  Liver cirrhosis 8 (1.4) 46 (5.8) <0.001 8 (1.7) 13 (2.7) 0.267
Hospital 
characteristics
  Teaching hospital 489 (86.2) 682 (86) 0.899 410 (86.3) 406 (85.5) 0.775
  Large hospital size 494 (87.1) 650 (82) 0.033 406 (85.5) 400 (84.2) 0.342
  Rural location 6 (1.1) 9 (1.1) 0.894 6 (1.3) 6 (1.3) 0.99
Non-elective 
admission
260 (45.8) 278 (35) <0.001 187 (39.4) 179 (37.7) 0.622
Mechanical 
prosthesis
0 (0) 305 (38.4) <0.001 0 (0) 203 (42.7) <0.001
Primary payer, n (%) 0.019 0.595
  Medicare/
Medicaid
315 (55.4) 506 (63.6) 275 (57.9) 271 (57.1)
  Private, including 
HMO
214 (37.6) 240 (30.2) 169 (35.6) 168 (35.4)
  Self-pay/no 
charge/other
18 (3.2) 25 (3.1) 15 (3.2) 16 (3.4)
Median income, n (%) 0.565 0.437
  1.0–25th 
percentile
159 (28.7) 200 (25.9) 135 (28.4) 126 (26.5)
  2.26–50th 
percentile
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Baseline 
characteristics 









  3.51–75th 
percentile
137 (24.7) 184 (23.8) 111 (23.4) 105 (22.1)
  4.76–100th 
percentile
130 (23.5) 193 (25) 116 (24.4) 117 (24.6)
HMO, health maintenance organisation;TVR, tricuspid valve replacement;TVr, tricuspid valve repair.
Table 1 Continued













In-hospital death 46 (8.1) 86 (10.8) 0.093 33 (6.9) 57 (12) 0.009
Permanent 
pacemaker
62 (10.9) 271 (34.1) <0.001 53 (11.2) 160 (33.7) <0.001
Stroke 13 (2.3) 10 (1.3) 0.146 9 (1.9) 7 (1.5) 0.804
Acute kidney injury 192 (33.7) 221 (27.8) 0.018 146 (30.7) 141 (29.7) 0.773
New dialysis 25 (4.4) 44 (5.5) 0.343 21 (4.4) 30 (6.3) 0.253
Blood transfusion 186 (32.7) 299 (37.6) 0.06 159 (33.5) 170 (35.8) 0.493
Cardiac tamponade 14 (2.5) 9 (1.1) 0.06 9 (1.9) 5 (1.1) 0.424
Pneumonia 49 (8.6) 54 (6.8) 0.21 36 (7.6) 32 (6.7) 0.708
Prolonged ventilation 42 (7.4) 45 (5.7) 0.2 29 (6.1) 37 (7.8) 0.389
Wound infection 6 (1.1) 16 (2) 0.166 5 (1.1) 12 (2.5) 0.143
Pulmonary embolism 23 (4) 20 (2.5) 0.112 16 (3.4) 17 (3.6) 0.99
Deep venous 
thrombosis




  Discharged home 408 (71.8) 557 (70.2) 348 (73.3) 324 (68.2) 0.003
  Discharged SNF/
NH/IC
114 (20.1) 147 (18.5) 94 (19.8) 92 (19.4) 0.801
Length of stay (days), 
mean (SD)
23 (26) 19 (24) 0.013 21 (26) 21 (28) 0.114
Postoperative length 
of stay
18 (21) 15 (20) 0.027 16 (22) 15 (20) 0.496
Length of stay >5 
days
483 (84.9) 690 (86.8) 0.317 395 (83.2) 413 (86.9) 0.018
Cost, mean (SD) $120 849 ($123 772) $84 637 ($8300) <0.001 $106 143 ($108 803) $91 316 ($86 768) <0.001
IC, intermediate care;NH, nursing home;SNF, skilled nursing facility;TVR, tricuspid valve replacement;TVr, tricuspid valve repair.
the inability to perform a meaningful volume-outcomes 
analysis due to the very low volume of TV surgery in 
the USA overall. Some of these factors, however, have 
been shown to play an important role on the operative 
mortality following TV surgery. The role of routine 
surveillance and early intervention was demonstrated 
in a Korean registry of 106 patients with rheumatic 
valvular disease and prior left-sided valve operations. 
These patients had worsening TR during follow-up and 
subsequently underwent TVR (50%) and TVr (50%), 
which were performed with a very low early operative 
mortality (1.9%).28 Similar low operative mortality of 
TVR and TVr has been demonstrated in other series.25 29 
In the study by Sung et al,29 the authors suggested their 
liberal use of modified ultrafiltration (95% of patients) 
was essential in reducing postoperative mortality. The 
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favourable effects of modified ultrafiltration (decreasing 
myocardial oedema, improving left ventricular func-
tion and improving pulmonary function compliance) 
have been demonstrated in non-TV cardiac surgical 
operations but can be quite useful in patients with TV 
disease due to the higher prevalence of right ventric-
ular failure and pulmonary hypertension.29–31 Further 
studies are required to assess the impact of early oper-
ations, surgical techniques and various postoperative 
management strategies on the outcomes of TV surgery 
in the contemporary era.
Major postoperative complications were not signifi-
cantly different between the two groups, with the 
exception of the rate of permanent pacemaker implan-
tation, which was threefold higher following TVR 
versus TVr. Similar findings were reported in prior 
smaller studies.32 33 Further studies are needed to 
assess the potential adverse impact of permanent pace-
maker implantation on long-term outcomes in these 
patients, especially given that one-third of patients 
undergoing TVR received a permanent pacemaker 
prior to discharge. A study by Jokinen et al32 showed 
that patients who received permanent pacemakers 
following TVR experienced a higher rate of throm-
boembolic complications and impaired quality of life 
during long-term follow-up. Hospital length of stay and 
frequency of non-home discharges were similar between 
the two groups. The modestly increased cost with TVr 
was therefore unexpected, particularly with the much 
lower rate of pacemaker implantation in this group. We 
speculated the following reasons to have contributed 
to this cost difference: (1) The TVr group had lower 
in-hospital mortality and longer length of stay. The 
excess number of death in the TVR group might have 
contributed to the lesser cost as these patients would 
have incurred more cost should have they survived to 
longer hospital stays. (2) The TVr group had higher 
incidence of patients admitted non-electively and hence 
they possibly incurred additional costs associated with 
emergency room charges, early diagnostic testing and 
so on, which might have played a role in the cost differ-
ence between TVR and TVr. (3) The difference in cost, 
although statistically significant, is modest and may be 
affected by unmeasured confounders that are difficult 
to ascertain in administrative databases. Nonetheless, 
further studies are needed to elucidate the underlying 
aetiology of this increased cost, such as the potential 
influence of right ventricular failure.
limitations
This study has several limitations. Although this is 
the largest nationwide study examining comparative 
outcomes of TVr versus TVR in patients with severe 
secondary TR, the results should be interpreted in 
the context of its limitations. (1) The NIS is a hospital 
claims database derived from ICD-9-CM codes and is 
therefore prone to coding inconsistencies. However, 
quality control measures are embedded in the Agency 
for Healthcare Research and Quality methodology to 
minimise these issues. In addition, the hard clinical 
endpoints in this study are difficult to miscode (death, 
pacemaker implantation, discharge status and so on). 
(2) We intended to study patients with secondary TR, 
and hence we excluded those with congenital heart 
disease and endocarditis. However, we cannot ascertain 
that these exclusion criteria were sufficient to identify 
a pure cohort of secondary TR. (3) A major limitation 
of this study is the inability to capture relevant data 
related to the nature and stage of TV disease (right 
ventricular dimension and function, pulmonary artery 
pressure, aetiology and duration of TV disease, left 
ventricular ejection fraction, and so on). We applied 
several layers of exclusions to arrive at a pure secondary 
TR population, but the lack of granular haemodynamic 
and echocardiographic data can possibly confound the 
results of the study, such as cost assessment. (4) Details 
on the urgency of surgery, surgical repair or replace-
ment techniques, perioperative medications and venti-
lation management, and long-term outcomes beyond 
hospital discharge are not available in the NIS. (5) The 
underlying mechanism of severe TR in a non-negligible 
number of patients undergoing TVR is pacemaker-re-
lated TV disease. In these patients the surgery might 
include removal and reimplantation of permanent 
pacemaker leads, and hence this can potentially falsely 
increase the rate of permanent pacemaker implanta-
tion in the TVR group.
ConClusions
Compared with TVR, TVr is associated with at least 
comparable in-hospital outcomes in patients with 
suitable anatomy for valve repair. Further studies are 
needed to understand the differential impact of the type 
of surgery on the short-term and long-term mortality in 
this complex undertreated population.
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